30/09/2022
16/04/2021
EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
12/02/2021
EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
30/11/2020
Call for more effective EU regulation of clinical trials with Advanced Therapy
Medicinal Products consisting of or containing Genetically Modified Organisms
19/10/2020
EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
09/03/2020
To ensure the EU remains a leader in ATMP innovation, this paper outlines and elaborates EuropaBio’s position and policy recommendations to the European Commission across three key focus areas.
15/01/2020
When “adult” blood causes illnesses, rejuvenating blood cells might be a remedy
30/11/2019
EuropaBio and its members strongly believe that genome editing will enable the development of many solutions to the grand challenges facing both people and planet.
28/02/2019
EuropaBio invites EU decision-makers to engage with us and our healthcare biotech members who are leading the field in advanced therapies.
19/02/2019
Read about the outcomes of our working policy breakfast in the European Parliament, hosted by MEPs Claudia Gamon and Tomislav Sokol, in cooperation with ARM, the Alliance for Regenerative Medicine.
27/09/2017
Possible solutions to improve the European regulatory procedures for clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms